Winlevi, the recently added anti-acne product with a new mechanism of action and broad-based use (vs Absorica), will further boost the derma portfolio and Speciality business growth
It’s an AB-rated generic therapeutic version of Durezol
It plays a pivotal role in monitoring pharmaceutical pricing
Demand normalisation post the second wave contributed to the steady growth
Anti-malaria API facility will be operational in 15-18 months
A treatment to prevent extreme symptoms and cut hospitalisation
Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030
The company has also applied to DCGI for Emergency Use Authorization (EUA) for ZyCoVD, the world's first Plasmid DNA Vaccine
The collaboration will support Canada with direct access to rapid pandemic response capabilities
Subscribe To Our Newsletter & Stay Updated
